Emmanuel Cabe, MD
Family Medicine · Fort Wayne, INNPI 1215928791
Payments from drug & device makers
Across 416 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$949
- AstraZeneca$879
- Bayer$844
- Lilly USA, LLC$794
- Exact Sciences$253
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 99 | $1,018 |
| AbbVie(2 entities) | 57 | $949 |
| AstraZeneca | 43 | $879 |
| Bayer | 61 | $844 |
| Lilly USA, LLC | 43 | $794 |
| Exact Sciences | 13 | $253 |
| Boehringer Ingelheim | 13 | $236 |
| GSK | 14 | $231 |
| Sanofi-aventis U.S. LLC | 11 | $203 |
| Pfizer | 9 | $147 |
| Abbott | 7 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $103 |
| Astellas Pharma US Inc | 5 | $99 |
| Novartis | 6 | $85 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Amgen | 3 | $39 |
| Dexcom, Inc. | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $30 |
| Merck | 2 | $28 |
| Antares Pharma, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Bioventus LLC | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
How this compares
$6,455 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 64 | $73,798 |
| OzempicSemaglutide | 36 | $43,643 |
| EliquisApixaban | 34 | $41,839 |
| MounjaroTirzepatide | 33 | $34,733 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $23,763 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $20,944 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $16,766 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $16,676 |
| JanuviaSitagliptin Phosphate | 11 | $16,559 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $15,586 |
| XareltoRivaroxaban | 14 | $13,660 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $13,159 |
| MyrbetriqMirabegron | 18 | $12,861 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $12,155 |
| Humalog Kwikpen U-100Insulin Lispro | 28 | $5,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $236 | $89,723101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $231 | $54,38763 claims |
| PfizerEliquis, Paxlovid | $147 | $44,58646 claims |
| Novo NordiskOzempic | $1,018 | $43,64336 claims |
| Lilly USA, LLCMounjaro | $794 | $34,73333 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $203 | $23,76314 claims |
| MerckJanuvia | $28 | $16,55911 claims |
| Johnson & JohnsonXarelto | $30 | $13,66014 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $12,86118 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,465305 claims |
| AbbVieSynthroid | $949 | $1,67316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.